Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineNo recent work listed

Na Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1081-756X; OpenAlex author ID A5102832562. Sources: OpenAlex.

Their work

Papers
3 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 3

  1. LEM domain containing 1 promotes pancreatic cancer growth and metastasis by p53 and mTORC1 signaling pathway. First author DOI 10.1080/21655979.2022.2047404↗
  2. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway. First author DOI 10.1002/jcp.29181↗
  3. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway. Co-author DOI 10.1002/mc.23011↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liming Tang · 3 shared papers, 2019–2022 · strength 0.40
  2. Yue Fu · 3 shared papers, 2019–2022 · strength 0.40
  3. Xiang Cao · 1 shared paper, 2022 · strength 0.16
  4. Qiuyang Chen · 1 shared paper, 2019 · strength 0.12
  5. Chunfu Zhu · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.